Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech have partnered to optimize and transfer the production process for ML7, a new compound for treating dry eye syndrome.
The companies have already partnered in developing a synthetic pathway for ML7, manufacturing the first non-GMP batches and devising associated analytical methods.
The process optimization phase to facilitate the transfer of the compound has been launched and the start of production on an industrial scale is scheduled for September 2012.
Neuroptis Biotech's chairman Eric Belot said, "Our collaboration with Provence Technologies has enabled us to have the first batches of ML7 not only on time but also to a level of purity that means we can proceed to the formulation and toxicity study stages with greater confidence."
ML7 has the potential to provide a targeted and effective therapeutic remedy for people suffering from dry eye syndrome, Gougerot-Sjogren syndrome and inflammations, especially ones caused by allergies.
